Daclatasvir discovery

[8] [2] [9] Feb 12, 2014 · The structure–activity relationship investigations that improved the exposure properties of the parent -phenylimidazole chemotype, culminating in the identification of the highly potent NS5A replication complex inhibitor daclatasvir () are described. In addition, a role of daclatasvir in the future therapy for HCV patients is discussed briefly

2024-03-29
    My dog ate motrin pm
  1. Daclatasvir was the first clinically approved NS5A inhibitor
  2. 2015
  3. Before using daclatasvir
  4. o2h discovery - seeding new ideas in life science, tech and green
  5. 020]
  6. 135 reported the promising results of a phase
  7. 009 and 0